Novartis is engaged in a year-end deal run, it seems. On Tuesday morning the pharma giant followed up its Conatus pact with news that it is buying Fort Worth-based Encore Vision after the biotech scored some positive early-stage data on their lead drug for presbyopia — a vision disorder that causes an inability to focus up close — boosting their ophthalmology pipeline. None of the terms were disclosed.
Hot on the heels of Clovis’ FDA OK for its PARP inhibitor rucaparib, Tesaro has gained a priority review schedule for its PARP niraparib. The drug, which has scored positive data, now faces an abbreviated June 30 PDUFA date.
Juno Therapeutics $JUNO has won a breakthrough drug designation for JCAR017, its lead prospect in the clinic following the implosion of JCAR015 after the deaths of 5 patients in their registration study.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription